UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
April 03, 2024 07:00 ET
|
Arch Biopartners
TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Anesthesia Clinical Trials Unit (ACTU), an...
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
April 02, 2024 07:26 ET
|
Arch Biopartners
TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have...
Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight Report 2024: Combining CDC7 Kinase Inhibitors with Existing Cancer Therapies for Enhanced Efficacy
January 11, 2024 05:28 ET
|
Research and Markets
Dublin, Jan. 11, 2024 (GLOBE NEWSWIRE) -- The "Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering. ...
USAN Approves Generic Name “Ruxoprubart” for NM8074, an Antibody Therapy focused on Complement-Mediated Diseases
January 08, 2024 08:30 ET
|
NovelMed Therapeutics Inc
The USAN Council has officially adopted "Ruxoprubart (Ruk”soe proo' bart)" as the generic name for NM8074, marking a significant milestone in the drug development process.Ruxoprubart is an...
Over 15 ATR Protein Inhibitors in Clinical Trials, Signifying Significant Advancements in Cancer Pharmaceutical Research
November 09, 2023 06:43 ET
|
Research and Markets
Dublin, Nov. 09, 2023 (GLOBE NEWSWIRE) -- The "Global ATR Protein Inhibitors Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering. A...
World Edema Clinical Trials (Phase I, Phase II, Phase III, Phase IV) Market Size, Share & Trends Analysis Report 2023-2030
November 06, 2023 06:23 ET
|
Research and Markets
Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "Edema Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Participant (Pediatrics,...
NovelMed Commences Phase II Trial for Anti-Bb Antibody (NM8074) in Treatment-Naïve PNH Patients: A Glimpse into the PNH Study Progress
October 30, 2023 08:00 ET
|
NovelMed Therapeutics Inc
The Phase I healthy trial revealed that NM8074 effectively blocked the alternative pathway (AP) and AP-mediated C3b deposition without affecting the classical pathway (CP). Importantly, NM8074 did not...
Navigating Trials in Crisis: A Comprehensive Look at Global COVID-19 and Long COVID Clinical Trials Amidst Disruptions
September 01, 2023 11:33 ET
|
Research and Markets
Dublin, Sept. 01, 2023 (GLOBE NEWSWIRE) -- The "Clinical Trials - Impact of COVID-19 and Long COVID" report has been added to ResearchAndMarkets.com's offering.This report provides an overview of...
Global KRAS Inhibitors Market Research Report 2023: A $4 Billion Opportunity by 2029, 200% Growth in 2022, 60 Drugs in Clinical Trials, 2 Approved Drugs
June 07, 2023 10:18 ET
|
Research and Markets
Dublin, June 07, 2023 (GLOBE NEWSWIRE) -- The "Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering. ...
Global Clinical Trials Market Report 2023: Globalized Drug Development Activities Bolsters Growth
April 12, 2023 08:08 ET
|
Research and Markets
Dublin, April 12, 2023 (GLOBE NEWSWIRE) -- The "Global Clinical Trials Market (2023-2028) by Study Phases, Study Designs, Indication of Disease and Geography, Impact of Covid-19 with Ansoff...